Novel lymphokine, monoclonal antibody specific to the lymphokine

Details Novel lymphokine, monoclonal antibody specific to the lymphokine Novel lymphokine, monoclonal antibody specific to the lymphokine

1988-07-21

1991-03-26

Nucker, Christine

Chemistry: molecular biology and microbiology

Micro-organism, tissue cell culture or enzyme using process...

Using tissue cell culture to make a protein or polypeptide

530351, C12P 2100

Patent

active

050028782

ABSTRACT:
A monoclonal antibody specific to the lymphokine, and its production is disclosed. The novel lymphokine LK2 is a glycoprotein with a molecular weight of 20,000.+-.2,000 daltons; isoelectric point pI, 6.2.+-.0.3; electrophoretic mobility Rf, 0.29.+-.0.02; cytotoxic on L 929 cells and substantially not growth-inhibitive on KB cell. The lymphokine significantly inhibits the growth of malignant human tumors in vivo. The monoclonal antibody may be of IgM or IgG class, and neutralizes specifically the cytotoxic activity of the lymphokine. Combined use of LK 2 with chemotherapeutic agents such as alkylating agents, metabolic antagonists, antioncotic antibiotics and plant alkaloids enhances greatly the antioncotic effect of the chemotherapeutics.

REFERENCES:
patent: 4276282 (1981-06-01), Sugimoto et al.
patent: 4285929 (1981-08-01), Sugimoto et al.
patent: 4758549 (1988-07-01), Mitsuhashi et al.
Biological Abstract, vol. 72, No. 5, 1981, p. 3282.

Affiliated with

Also associated with

Rating

Novel lymphokine, monoclonal antibody specific to the lymphokine does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Novel lymphokine, monoclonal antibody specific to the lymphokine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Novel lymphokine, monoclonal antibody specific to the lymphokine will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-616892